MedPath

FDA Approves New Drug for Advanced Parkinson's Disease

The FDA has approved a new drug aimed at treating advanced Parkinson's Disease, a movement disorder affecting the central nervous system, with tremor being a common symptom.

Thousands of Americans are diagnosed every year with Parkinson’s Disease, a movement disorder that affects the central nervous system, with tremor being a common symptom. The Food and Drug Administration recently approved a new drug for those living with advanced Parkinson’s. Movement disorders neurologist Dr. Leon Meytin with Hartford HealthCare’s Ayer Neuroscience Institute discussed the implications of this approval.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Bayer's Cell and Gene Therapy Programs for Parkinson's Disease Enter Clinical Trials

Bayer's BlueRock Therapeutics initiated a Phase 1 trial of DA01, a cell-based therapy using stem cell-derived dopaminergic neurons, to replenish lost neurons in Parkinson's patients.
AskBio, another Bayer subsidiary, has begun a Phase 1b trial of its gene therapy for Parkinson's, aiming to halt or reverse motor control decline by delivering a gene for glial cell line-derived neurotrophic factor (GDNF).

Neurocrine Biosciences' Crinecerfont Receives FDA Approval for Congenital Adrenal Hyperplasia

The FDA has approved Crinecerfont, developed by Neurocrine Biosciences, as the first drug in decades for congenital adrenal hyperplasia (CAH).
Crinecerfont is designed to reduce elevated androgen levels in individuals with CAH, addressing a critical unmet need in current treatment.

New Drug Shows Promise in Alleviating Parkinson's Disease Symptoms in Late-Stage Study

A novel drug has demonstrated potential in reducing the severity of motor symptoms associated with Parkinson's disease, offering hope for improved daily functioning.
The late-stage study assessed the drug's efficacy in alleviating tremors and stiffness, common challenges faced by individuals living with Parkinson's disease.

TrueBinding's TB006 Receives FDA IND Clearance for Phase 2a Parkinson's Disease Trial

TrueBinding's TB006, a monoclonal antibody targeting Galectin-3, has received FDA IND clearance for a Phase 2a trial in Parkinson's Disease, marking a significant milestone.
The Phase 2a trial will assess the safety and efficacy of TB006 in early to mild Parkinson's patients aged 50-80, with an estimated enrollment of 62 participants.

Nipocalimab Granted FDA Breakthrough Therapy Designation for Sjögren's Disease

Nipocalimab, a novel neonatal Fc receptor blocker, has received Breakthrough Therapy Designation from the FDA for moderate to severe Sjögren's disease.
This monoclonal antibody is the first investigational therapy to receive this designation for Sjögren’s, highlighting its potential to address the underlying causes.

FDA Approves AbbVie's Vyalev for Advanced Parkinson's Disease

The FDA has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour levodopa-based infusion for advanced Parkinson's disease.
Clinical trials demonstrated that Vyalev significantly increased "on" time without troublesome dyskinesia by 2.72 hours compared to 0.97 hours with oral carbidopa/levodopa.

FDA Approves AbbVie's Vyalev for Advanced Parkinson's Disease

The FDA has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) as a 24-hour subcutaneous infusion for motor fluctuations in advanced Parkinson's disease.
Vyalev is the first and only levodopa-based therapy delivered as a continuous 24-hour infusion, offering a non-surgical treatment option for patients.

Medtronic Gains FDA Approvals for Percept and Inceptiv Systems

Medtronic's Percept system, a 'pacemaker for the brain,' received FDA approval for managing movement disorders like Parkinson's disease by sending electrical signals to modulate brain rhythms.
The Inceptiv spinal cord stimulator, designed for chronic pain treatment, secured FDA approval with its unique ability to automatically adjust therapy, enhancing pain relief and maintaining stimulation levels.

FDA Approves Crexont for Parkinson's Disease Treatment

The FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for Parkinson's disease, offering a novel oral formulation.
Crexont combines immediate-release granules and extended-release pellets, aiming to provide longer 'Good On' time with less frequent dosing.

BlueRock Therapeutics' Bemdaneprocel Receives FDA RMAT Designation for Parkinson's Disease

BlueRock Therapeutics' bemdaneprocel, a cell therapy for Parkinson's disease, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
The RMAT designation allows for expedited development review and planning guidance from the FDA, potentially accelerating the path to approval.

Reference News

[1]
FDA approves new drug for advanced Parkinson's Disease
yahoo.com · Jan 3, 2025

Thousands diagnosed annually with Parkinson’s, a central nervous system disorder causing tremors. FDA approved a new dru...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy